Clinical Trial Detail

NCT ID NCT02452424
Title A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Plexxikon
Indications

stomach cancer

melanoma

lung non-small cell carcinoma

triple-receptor negative breast cancer

pancreatic ductal carcinoma

urinary bladder cancer

head and neck squamous cell carcinoma

ovarian cancer

Advanced Solid Tumor

Therapies

Pembrolizumab + Pexidartinib

Age Groups: adult

No variant requirements are available.